

MONETARY POLICY

SBP jacks up Policy Rate by another 125bps on the back of inflation concerns

Thursday, July 7, 2022


- The MPC, in its meeting held today increased Policy rate by another 125bps to pull it to 15%, last seen post the 2008 global financial crisis. The decision was primarily based on multi-year high inflation readings (Jun-22 CPI: 21.3%), which are expected to remain at elevated levels for the next fiscal year.
- The SBP committee cited that FY23 will be a year of consolidation where a mix of fiscal and monetary tools will be used to dampen demand, increase tax collection, reduce the import bill and ease off pressure building on the PKR.
- The committee expects inflation to average at around 18-20% in FY23 where we can expect moderation from the second half of the fiscal year before declining sharply to 5-7% towards the end of FY24.
- GDP growth targets have been trimmed slightly from 3.5-4.5% to 3-4% compared to ~6% in FY22 to make it more sustainable going forward.
- The MPC shared optimism with regards to successful resumption of the IMF program and highlighted that the harder part (reversals of energy subsidies and approval of the Federal Budget) of getting the program back on the track has been completed. The committee expects Staff Level Agreement to be reached in the next few weeks.
- As for fiscal, the MPC expects a strong comeback in FY23 and forecasts a surplus of 0.2% of GDP on the back of improved tax collection against 2.4% deficit noted in FY22. While for CAD, the committee expects it to slow down to 3% of GDP in FY23.
- In the light of the above developments, we recommend a low risk investment strategy with primary exposure in cash rich, low-beta and high yielding scrips in the Banks, E&P's and Fertilizers space while shying away from high beta, leveraged and cyclical plays.

Inflation continues to be the main concern: MPC cited expectations of high teens average inflation in FY23 to be the main reason behind the 125bps rate hike. SBP was of the view that global economic conditions continue to remain dynamic and multi-decade high commodity prices will dictate inflation readings going forward. The move is aimed at moderating domestic growth which has now surpassed pre-Covid levels and consistent ~6% annual GDP growth in the previous two fiscal years is not sustainable for Pakistan as it leads to inflationary pressures, high import bill and PKR devaluation. SBP expects a combination of fiscal consolidation and monetary tightening tools to address the situation alongside support from exports and remittances flow. On the brighter side, the SBP expects inflation readings to come off drastically from the next fiscal year to a more sustainable rate of 5-7%.

Staff Level Agreement with the IMF is not a long way off: The committee reiterated that IMF negotiations have been progressing fruitfully and major adjustments which included the roll-back of energy subsidies and modifications to the Federal Budget have been addressed. Hence, the regulator expects Staff Level Agreement to be reached soon which will pave the way for inflows from other bilateral/multilateral/commercial sources, which will not only help in bridging the external funding gap but also shore up forex reserves.

SBP's take on the PKR: Apart from the monetary action taken by the SBP to stabilize the PKR, the MPC expects fiscal surplus on the back of improved tax collection, reduced energy imports as domestic demand tapers off and support from both exports & remittances flow to strengthen the PKR going forward.

Chart 1: Policy Rate history



Source: SBP, BMA Research

Abdul Rehman Siddiqui

Deputy Head of Research

Tel: 111-262-111 ext. 2056

E-mail: abdul.rehman@bmacapital.com

BMA Capital Management Ltd.

Disclaimer

This research report is for information purposes only and does not constitute nor is it intended as an offer or solicitation for the purchase or sale of securities or other financial instruments. Neither the information contained in this research report nor any future information made available with the subject matter contained herein will form the basis of any contract. Information and opinions contained herein have been compiled or arrived at by BMA Capital Management Limited from publicly available information and sources that BMA Capital Management Limited believed to be reliable. Whilst every care has been taken in preparing this research report, no research analyst, director, officer, employee, agent or adviser of any member of BMA Capital Management Limited gives or makes any representation, warranty or undertaking, whether express or implied, and accepts no responsibility or liability as to the reliability, accuracy or completeness of the information set out in this research report. Any responsibility or liability for any information contained herein is expressly disclaimed. All information contained herein is subject to change at any time without notice. No member of BMA Capital Management Limited has an obligation to update, modify or amend this research report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. Furthermore, past performance is not indicative of future results.

The investments and strategies discussed herein may not be suitable for all investors or any particular class of investor. Investors should make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives when investing. Investors should consult their independent advisors if they have any doubts as to the applicability to their business or investment objectives of the information and the strategies discussed herein. This research report is being furnished to certain persons as permitted by applicable law, and accordingly may not be reproduced or circulated to any other person without the prior written consent of a member of BMA Capital Management Limited. This research report may not be relied upon by any retail customers or person to whom this research report may not be provided by law. Unauthorized use or disclosure of this research report is strictly prohibited. Members of BMA Capital Management and/or their respective principals, directors, officers and employees may own, have positions or effect transactions in the securities or financial instruments referred herein or in the investments of any issuers discussed herein, may engage in securities transactions in a manner inconsistent with the research contained in this research report and with respect to securities or financial instruments covered by this research report, may sell to or buy from customers on a principal basis and may serve or act as director, placement agent, advisor or lender, or make a market in, or may have been a manager or a co-manager of the most recent public offering in respect of any investments or issuers of such securities or financial instruments referenced in this research report or may perform any other investment banking or other services for, or solicit investment banking or other business from any company mentioned in this research report. Investing in Pakistan involves a high degree of risk and many persons, physical and legal, may be restricted from dealing in the securities market of Pakistan. Investors should perform their own due diligence before investing. No part of the compensation of the authors of this research report was, is or will be directly or indirectly related to the specific recommendations or views contained in the research report. By accepting this research report, you agree to be bound by the foregoing limitations.

BMA Capital Management Limited and / or any of its affiliates, which operate outside Pakistan, do and seek to do business with the company(s) covered in this research document. Investors should consider this research report as only a single factor in making their investment decision. BMA Research Policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer/company prior to the publication of a research report containing such rating, recommendation or investment thesis.

Stock Rating

Investors should carefully read the definitions of all rating used within every research reports. In addition, research reports carry an analyst's independent view and investors should ensure careful reading of the entire research reports and not infer its contents from the rating ascribed by the analyst. Ratings should not be used or relied upon as investment advice. An investor's decision to buy, hold or sell a stock should depend on said individual's circumstances and other considerations. BMA Capital Limited uses a three tier rating system: i) Buy, ii) Neutral and iii) Underperform (new rating system effective Jan 1'18) with our rating being based on total stock returns versus BMA's index target return for the year. A table presenting BMA's rating definitions is given below:

Buy	>15% expected total return
Hold	10%-15% expected total return
Underperform	<10% expected total return
*Total stock return = capital gain + dividend yield	

Old rating system

Overweight	Total sector return > expected market return
Marketweight	Expected market return
Underweight	Total stock return < expected market return

Valuation Methodology

To arrive at our period end target prices, BMA Capital uses different valuation methodologies including

- Discounted cash flow (DCF, DDM)
- Relative Valuation (P/E, P/B, P/S etc.)
- Equity & Asset return based methodologies (EVA, Residual Income etc.)